Your Source for Venture Capital and Private Equity Financings

Aro Biotherapeutics Secures $88M Series A

PHILADELPHIA, PA, Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, announced the closing of an $88 million Series A financing.
Northpond Ventures and Cowen Healthcare Investments led the round, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation - JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. also participated in the round. Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease. The proceeds from the Series A will be used to advance the company's lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors